Xing Zhao, MD PhD

Founder, Chairman, Global CEO of ReLive

Xing Zhao, MD PhD, is Managing Director of CO.DON GmbH since March 2023, and the Chairman and Global CEO of ReLive Biotechnologies since 2021.

Xing received his PhD in Regenerative Medicine and Life Sciences from Utrecht University in the Netherlands and conducted postdoctoral research fellowship at Massachusetts General Hospital and Harvard Medical School in the US, focusing on Tissue Engineering and Regenerative Medicine for cartilage repair and regeneration.

Xing has more than 15 years of experience in clinical practice, scientific discovery, innovative cell product development, and investments in the biotechnological field, particularly in regenerative medicine and cell therapy. In 2010, he became an Instructor of Orthopedic Surgery at Harvard Medical School. In 2015, he served as the Head of Research and the Chairman of the Scientific Advisory Board at Vericel Corporation (NASDAQ: VCEL), a leading regenerative medicine company in the US. As a venture capitalist, he has invested in several biotech startups in the US.

In 2021, he founded ReLive Biotechnologies, a global regenerative medicine company group focused on Orthopedics, Plastic, and Reconstructive Surgery, operating in United States, Europe, and China, which acquired all assets from CO.DON AG in January 2023.